VivoSeq
Other

Progeria

0

Pipeline Programs

0

Active Trials

0

Companies Involved

Progeria is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

3

clinical trials

Unknown status2 · 67%
Completed1 · 33%

Trial Activity

Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria
Unknown status··Phase 2·NCT00916747·85 enrolled
Phase I/II Trial of Everolimus in Combination With Lonafarnib in Progeria
Unknown status··Phase 1/2·NCT02579044·80 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)